Table 2. Progression-Free Survival

Slides:

Advertisements

Similar presentations

1 times table 2 times table 3 times table 4 times table 5 times table

Advertisements

$100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300.

Tables Learning Support

Marker SFRP1 SFRP2 SFRP5 DKK3 WIF1 APC CDH1 Unmethylated Methylated A

ESMO 2016 Durvalumab Data Study / Abstract Ph Indication Line N Arms

A cura di Filippo de Marinis

Copyright © 2015 American Medical Association. All rights reserved.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Table 1. Patient Characteristics

Presented By Michael Lee at 2016 ASCO Annual Meeting

Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al

Oncol Res Treat 2016;39: DOI: /

Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network

Table 1 Baseline patient characteristics

Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large.

Tips Need to Consider When Organizing a College Event

Survival Outcomes at 3 Years

ماجستير إدارة المعارض من بريطانيا

Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network

Volume 150, Issue 3, Pages (September 2018)

Volume 65, Issue 6, Pages (June 2014)

by Michael F. Leahy, and J. Harvey Turner

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

A–d) Comparison of Kaplan–Meier curves of a) progression-free survival (PFS) and c) overall survival (OS) in large-cell neuroendocrine carcinoma (LCNEC)

Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non–Small Cell Lung Cancer: A Phase II Clinical Trial

Treatment of Locally Advanced Pancreatic Cancer

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer Denis Soulières, MD, Fred R.

Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p by James I. Barnes, Vasu Divi,

ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated.

A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin- Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer:

Overview of the QTWiST method

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

CYCLE 1A Supplemental Figure

PRISMA study flow diagram

A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary.

Supplementary Figure 2 Shiota et al.

Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK–Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External.

(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.

Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases

Volume 152, Issue 1, Pages (January 2019)

PFS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients (n=34). mPFS, median.

Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase.

Forest plots for all drugs (OS and PFS HRs combined): excellent versus reduced PS comparison and ECOG PS levels comparison (see online supplementary 1). ECOG.

Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy Sophie Papa, MRCP, PhD, Sanjay Popat, FRCP,

3 times tables.

6 times tables.

High volume Low volume HORRAD STAMPEDE Failure-free survival

KRAS Mutations in Advanced Nonsquamous Non–Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy Have No Predictive Value

Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

Definition of health states

Prospective Assessment of Continuation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition.

Figure 2. Biomarkers for prediction of differences in PFS and objective response rate between GP and GT arm in patients ... Figure 2. Biomarkers for prediction.

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

Pre-Transplant Comorbidity As an Outcome Predictor in Hematopoietic Cell Transplantation for Severe Aplastic Anemia SungNam Lim, Je-Hwan Lee, MD, PhD,

Fig. 1. Kaplan-Meier curves for PFS and OS

Unadjusted event-free survival (days alive and out-of-hospital) of participants with and without MCI in (A) overall cohort, (B) standard management cohort.

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

Autologous Stem Cell Transplantation for POEMS Syndrome

(A) Survival curves according to clinical response.

Fig. 2. Kaplan-Meier plots for PFS and OS of 37 patients according to histological diagnosis (A and D), the extent of tumor resection (B and E), and adjuvant.

Progression and survival analysis.

A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an.

* OS >3yr with No Next Line * * * * *

Presentation transcript:

Table 2. Progression-Free Survival DP Arm MVP Arm PFS Event Rate 95% CI 95%CI 1 year 46 53.4% 43.1–62.6 55 45.5% 35.7–54.9 2 year 65 33.9% 24.7–43.2 71 29.7% 21.1–38.8 3 year 75 23.3% 15.4–32.1 25.7% 17.7–34.5 4 year 80 18.0% 11.1–26.3 84 16.8% 10.3–24.7

Table 3. Overall Survival DP Arm MVP Arm OS Event Rate 95% CI 95%CI 1 year 17 82.8% 73.8–88.9 32 68.2% 58.2–76.4 2 year 39 60.3% 49.9–69.2 52 48.5% 38.4–57.8 3 year 62 36.4% 26.9–45.9 61 39.4% 29.8–48.8 4 year 73 24.7% 16.5–33.6 78 22.2% 14.7–30.8